ALNYLAM PHARMACEUTICALS INC ALNY
ASignal's systematic analysis rates ALNY as Neutral.
Reflects the latest available analysis · analyzed Nov 15, 2026
The case on ALNY
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong free cash flow generation ($327.23M)
- High gross margin (77.28%) indicating pricing power
- Exceptional return on equity (138.07%)
- Revenue growth of 16.7% YoY
- Earnings growth of 633.5% YoY
- Low debt-to-equity ratio (0.83x)
- Negative MACD histogram (-0.89) showing weakening momentum
- Price below both SMA20 (187.38) and SMA50 (219.25), indicating downtrend
- No Reddit mentions, suggesting lack of retail interest or sentiment data
- Forward P/E (15.24x) higher than current P/E (8.34x), implying earnings expectations may be priced in
See the full verdict on ALNY
ASignal Rank (1-4), confidence score, Value / Activist / Macro grades, price targets, and the full reasoning behind the call.
How ASignal analyzes ALNY
Most investors never get a second opinion, let alone several. ASignal runs ALNY past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: value discipline, activist catalysts, and macro analysis. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.